{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:52:13Z","timestamp":1761094333978,"version":"build-2065373602"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,21]]},"DOI":"10.7759\/cureus.95066","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:19:49Z","timestamp":1761059989000},"source":"Crossref","is-referenced-by-count":0,"title":["Prognostic Factors in Metastatic Urothelial Carcinoma Treated Without Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (M-VAC): A Single-Center Retrospective Study"],"prefix":"10.7759","author":[{"given":"Irfan","family":"Bugday","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mevlude","family":"Inanc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Metin","family":"Ozkan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oktay","family":"Bozkurt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramazan","family":"Cosar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sedat T","family":"Firat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emel","family":"Mutlu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murat","family":"Eser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet K","family":"Disli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammet","family":"Cengiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"American Cancer Society. Key statistics for bladder cancer. (2016). Accessed. May 20, 2025: https:\/\/www.cancer.org\/cancer\/types\/bladder-cancer\/about\/key-statistics.html?utm_source."},{"key":"ref2","unstructured":"NIH NCI. Surveillance, Epidemiology, and End Results Program. Cancer stat facts: bladder cancer. (2023). Accessed: February 8, 2024: https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/0090-4295(80)90067-9","article-title":"Metastases from transitional cell carcinoma of urinary bladder","volume":"16","author":"Babaian RJ","year":"1980","unstructured":"Babaian RJ, Johnson DE, Llamas L, Ayala AG. Metastases from transitional cell carcinoma of urinary bladder. Urology. 1980, 16:142-4. 10.1016\/0090-4295(80)90067-9","journal-title":"Urology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(17)48996-8","article-title":"Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium","volume":"133","author":"Sternberg CN","year":"1985","unstructured":"Sternberg CN, Yagoda A, Scher HI, et al.. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol. 1985, 133:403-7. 10.1016\/s0022-5347(17)48996-8","journal-title":"J Urol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase H","year":"2000","unstructured":"von der Maase H, Hansen SW, Roberts JT, et al.. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000, 18:3068-77. 10.1200\/JCO.2000.18.17.3068","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.10.3173","article-title":"Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy","volume":"17","author":"Bajorin DF","year":"1999","unstructured":"Bajorin DF, Dodd PM, Mazumdar M, et al.. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999, 17:3173-81. 10.1200\/JCO.1999.17.10.3173","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase H","year":"2005","unstructured":"von der Maase H, Sengelov L, Roberts JT, et al.. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005, 23:4602-8. 10.1200\/JCO.2005.07.757","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4599","article-title":"Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens","volume":"28","author":"Bellmunt J","year":"2010","unstructured":"Bellmunt J, Choueiri TK, Fougeray R, et al.. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol. 2010, 28:1850-5. 10.1200\/JCO.2009.25.4599","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/418063-prognostic-factors-in-metastatic-urothelial-carcinoma-treated-without-methotrexate-vinblastine-doxorubicin-and-cisplatin-m-vac-a-single-center-retrospective-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:19:53Z","timestamp":1761059993000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/418063-prognostic-factors-in-metastatic-urothelial-carcinoma-treated-without-methotrexate-vinblastine-doxorubicin-and-cisplatin-m-vac-a-single-center-retrospective-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":8,"URL":"https:\/\/doi.org\/10.7759\/cureus.95066","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,21]]}}}